It is a pity that POET so far did not see the necessarity to release news about such "nifty things" like patents. Every pharma startup would love to publish such material info to the market, as this is finally creating the value of a pre-revenue company. It also would honor our good Dr.GT.

Oh well, it would be so nice if POET would care about their SP - at least from time to time...

I hope the new IR is consulting them in this respect.